Skip to main content

Efficacy of Surface-Modified PLGA Nanoparticles as a Function of Cervical Cancer Type

Pharmaceutical Research volume 36, Article number: 66 (2019) Cite this article

Abstract

Purpose

Hypovascularization of cervical tumors, coupled with intrinsic and acquired drug resistance, has contributed to marginal therapeutic outcomes by hindering chemotherapeutic transport and efficacy. Recently, the heterogeneous penetration and distribution of cell penetrating peptide (CPP, here MPG) and polyethylene glycol (PEG) modified poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) were evaluated as a function of tumor type and morphology in cervical cancer spheroids modeling hypovascularized tumor nodules. Building upon this work, this study investigates the efficacy imparted by surface-modified Doxorubicin-loaded NPs transported into hypovascularized tissue.

Methods

NP efficacy was measured in HeLa, CaSki, and SiHa cells. NP internalization and association, and associated cell viability, were determined in monolayer and spheroid models.

Results

MPG and PEG-NP co-treatment was most efficacious in HeLa cells, while PEG NPs were most efficacious in CaSki cells. NP surface-modifications were unable to improve efficacy, relative to unmodified NPs, in SiHa cells.

Conclusions

The results highlight the dependence of efficacy on tumor type and the associated microenvironment. The results further relate previous NP transport studies to efficacy, as a function of surface-modification and cell type. Longer-term, this information may help guide the design of NP-mediated strategies to maximize efficacy based on patient-specific cervical tumor origin and characteristics.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 39.95

Price includes VAT (USA)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Abbreviations

AUC:

Area under the curve

C6:

Coumarin 6

CPP:

Cell penetrating peptide

DCM:

Methylene chloride

diH2O:

Deionized water

Dox:

Doxorubicin

EPR:

Enhanced permeability and retention

FRT:

Female reproductive tract

HPV:

Human papilloma virus

MDR:

Multi-drug resistant

MEM:

Minimum essential media

MFI:

Mean fluorescence intensity

NaDC:

Sodium deoxycholate

NP:

Nanoparticle

o/w:

Oil-in-water

PA-NHS:

Palmitic acid-N-hydroxysuccinimide ester

PBS:

Phosphate buffered saline

PEG:

Polyethylene glycol

Pgp:

P-glycoprotein

PLGA:

Poly(lactic-co-glycolic) acid

PVA:

Polyvinyl alcohol

RPMI:

Roswell Park Memorial Institute medium

SEM:

Scanning electron microscopy

References

  1. Hockel S, Schlenger K, Vaupel P, Hockel M. Association between host tissue vascularity and the prognostically relevant tumor vascularity in human cervical cancer. Int J Oncol. 2001;19(4):827–32.

    CAS  PubMed  Google Scholar 

  2. Au JL, Jang SH, Wientjes MG. Clinical aspects of drug delivery to tumors. J Control Release. 2002;78(1–3):81–95.

    CAS  PubMed  Article  Google Scholar 

  3. Cukierman E, Khan DR. The benefits and challenges associated with the use of drug delivery systems in cancer therapy. Biochem Pharmacol. 2010;80(5):762–70.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  4. Grantab R, Sivananthan S, Tannock IF. The penetration of anticancer drugs through tumor tissue as a function of cellular adhesion and packing density of tumor cells. Cancer Res. 2006;66(2):1033–9.

    CAS  PubMed  Article  Google Scholar 

  5. Kuh HJ, Jang SH, Wientjes MG, Weaver JR, Au JL. Determinants of paclitaxel penetration and accumulation in human solid tumor. J Pharmacol Exp Ther. 1999;290(2):871–80.

    CAS  PubMed  Google Scholar 

  6. Tredan O, Galmarini CM, Patel K, Tannock IF. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst. 2007;99(19):1441–54.

    CAS  PubMed  Article  Google Scholar 

  7. Gupta S, Gupta MK. Possible role of nanocarriers in drug delivery against cervical cancer. Nano Rev Exp. 2017;8:1–25.

    CAS  Article  Google Scholar 

  8. Kijanka M, Dorresteijn B, Oliveira S, van Bergen EN, Henegouwen PM. Nanobody-based cancer therapy of solid tumors. Nanomedicine (Lond). 2015;10(1):161–74.

    CAS  PubMed  Article  Google Scholar 

  9. Lee BK, Yun YH, Park K. Smart nanoparticles for drug delivery: boundaries and opportunities. Chem Eng Sci. 2015;125:158–64.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  10. Parveen S, Misra R, Sahoo SK. Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging. Nanomedicine. 2012;8(2):147–66.

    CAS  PubMed  Article  Google Scholar 

  11. Zeng X, Tao W, Mei L, Huang L, Tan C, Feng SS. Cholic acid-functionalized nanoparticles of star-shaped PLGA-vitamin E TPGS copolymer for docetaxel delivery to cervical cancer. Biomaterials. 2013;34(25):6058–67.

    CAS  PubMed  Article  Google Scholar 

  12. Gutierrez-Iglesias G, Hurtado Y, Palma-Lara I, Lopez-Marure R. Resistance to the antiproliferative effect induced by a short-chain ceramide is associated with an increase of glucosylceramide synthase, P-glycoprotein, and multidrug-resistance gene-1 in cervical cancer cells. Cancer Chemother Pharmacol. 2014;74(4):809–17.

    CAS  PubMed  Article  Google Scholar 

  13. Lopes-Rodrigues V, Sousa E, Vasconcelos MH. Curcumin as a Modulator of P-Glycoprotein in Cancer: Challenges and Perspectives. Pharmaceuticals. 2016;9(4).

    PubMed Central  Article  Google Scholar 

  14. Grigore ME. Organic and inorganic Nano-Systems used in Cancer treatment. Journal of Medical Research and Health Education. 2017;1.

  15. Duman FD, Erkisa M, Khodadust R, Ari F, Ulukaya E, Acar HY. Folic acid-conjugated cationic Ag2S quantum dots for optical imaging and selective doxorubicin delivery to HeLa cells. Nanomedicine (Lond). 2017;12(19):2319–33.

    CAS  Article  Google Scholar 

  16. Zhitnyak IY, Bychkov IN, Sukhorukova IV, Kovalskii AM, Firestein KL, Golberg D, et al. Effect of BN nanoparticles loaded with doxorubicin on tumor cells with multiple drug resistance. ACS Appl Mater Interfaces. 2017;9(38):32498–508.

    CAS  PubMed  Article  Google Scholar 

  17. Wu GC, Wang ZZ, Bian XS, Du XJ, Wei CH. Folate-modified doxorubicin-loaded nanoparticles for tumor-targeted therapy. Pharm Biol. 2014;52(8):978–82.

    CAS  PubMed  Article  Google Scholar 

  18. Sims LB, Curtis LT, Frieboes HB, Steinbach-Rankins JM. Enhanced uptake and transport of PLGA-modified nanoparticles in cervical cancer. Journal of nanobiotechnology. 2016;14:33.

    PubMed  PubMed Central  Article  Google Scholar 

  19. Sims LB, Huss MK, Frieboes HB, Steinbach-Rankins JM. Distribution of PLGA-modified nanoparticles in 3D cell culture models of hypo-vascularized tumor tissue. Journal of nanobiotechnology. 2017;15(1):67.

    PubMed  PubMed Central  Article  Google Scholar 

  20. Gorodeski GI, Jin W, Hopfer U. Extracellular Ca2+ directly regulates tight junctional permeability in the human cervical cell line CaSki. Am J Phys. 1997;272(2 Pt 1):C511–24.

    CAS  Article  Google Scholar 

  21. Hoppe-Seyler K, Honegger A, Bossler F, Sponagel J, Bulkescher J, Lohrey C, et al. Viral E6/E7 oncogene and cellular hexokinase 2 expression in HPV-positive cancer cell lines. Oncotarget. 2017;8(63):106342–51.

    PubMed  PubMed Central  Article  Google Scholar 

  22. Aasen T, Hodgins MB, Edward M, Graham SV. The relationship between connexins, gap junctions, tissue architecture and tumour invasion, as studied in a novel in vitro model of HPV-16-associated cervical cancer progression. Oncogene. 2003;22(39):7969–80.

    PubMed  Article  Google Scholar 

  23. de la Puente P, Muz B, Gilson RC, Azab F, Luderer M, King J, et al. 3D tissue-engineered bone marrow as a novel model to study pathophysiology and drug resistance in multiple myeloma. Biomaterials. 2015;73:70–84.

    PubMed  PubMed Central  Article  Google Scholar 

  24. Ordikhani F, Kim Y, Zustiak SP. The role of biomaterials on Cancer stem cell enrichment and behavior. Jom-Us. 2015;67(11):2543–9.

    CAS  Article  Google Scholar 

  25. Filippova M, Filippov V, Williams VM, Zhang K, Kokoza A, Bashkirova S, et al. Cellular levels of oxidative stress affect the response of cervical cancer cells to chemotherapeutic agents. Biomed Res Int. 2014;2014:574659.

    PubMed  PubMed Central  Article  Google Scholar 

  26. Steinbach JM, Seo YE, Saltzman WM. Cell penetrating peptide-modified poly(lactic-co-glycolic acid) nanoparticles with enhanced cell internalization. Acta Biomater. 2016;30:49–61.

    CAS  PubMed  Article  Google Scholar 

  27. Fahmy TM, Samstein RM, Harness CC, Saltzman WM. Surface modification of biodegradable polyesters with fatty acid conjugates for improved drug targeting. Biomaterials. 2005;26(28):5727–36.

    CAS  PubMed  Article  Google Scholar 

  28. Martin DT, Steinbach JM, Liu JC, Shimizu S, Kaimakliotis HZ, Wheeler MA, et al. Surface-modified nanoparticles enhance Transurothelial penetration and delivery of Survivin siRNA in treating bladder Cancer. Mol Cancer Ther. 2014;13(1):71–81.

    CAS  PubMed  Article  Google Scholar 

  29. Li J, Feng L, Fan L, Zha Y, Guo L, Zhang Q, et al. Targeting the brain with PEG-PLGA nanoparticles modified with phage-displayed peptides. Biomaterials. 2011;32(21):4943–50.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  30. Cu Y, Booth CJ, Saltzman WM. In vivo distribution of surface-modified PLGA nanoparticles following intravaginal delivery. J Control Release. 2011;156(2):258–64.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  31. Woodrow KA, Cu Y, Booth CJ, Saucier-Sawyer JK, Wood MJ, Saltzman WM. Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNA. Nat Mater. 2009;8(6):526–33.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  32. Beáta Tóth PK, Rémi Magnan. Membrane transporters and transporter substrates as biomarkers for drug pharmacokinetics, pharmacodynamics, and toxicity/adverse events. In: Press A, editor. Biomarkers in Toxicology: Academic Press; 2014. p. 947–963.

  33. Kibria G, Hatakeyama H, Akiyama K, Hida K, Harashima H. Comparative study of the sensitivities of cancer cells to doxorubicin, and relationships between the effect of the drug-efflux pump P-gp. Biol Pharm Bull. 2014;37(12):1926–35.

    CAS  PubMed  Article  Google Scholar 

  34. Nanayakkara AK, Follit CA, Chen G, Williams NS, Vogel PD, Wise JG. Targeted inhibitors of P-glycoprotein increase chemotherapeutic-induced mortality of multidrug resistant tumor cells. Sci Rep. 2018;8(1):967.

    PubMed  PubMed Central  Article  Google Scholar 

  35. Baek N, Seo OW, Kim M, Hulme J, An SS. Monitoring the effects of doxorubicin on 3D-spheroid tumor cells in real-time. Onco Targets Ther. 2016;9:7207–18.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  36. Lopez J, Valdez-Morales FJ, Benitez-Bribiesca L, Cerbon M, Carranca AG. Normal and cancer stem cells of the human female reproductive system. Reprod Biol Endocrinol. 2013;11:53.

    PubMed  PubMed Central  Article  Google Scholar 

  37. Siadat-Pajouh M, Periasamy A, Ayscue AH, Moscicki AB, Palefsky JM, Walton L, et al. Detection of human papillomavirus type 16/18 DNA in cervicovaginal cells by fluorescence based in situ hybridization and automated image cytometry. Cytometry. 1994;15(3):245–57.

    CAS  PubMed  Article  Google Scholar 

  38. Hoppe-Seyler K, Bossler F, Lohrey C, Bulkescher J, Rosl F, Jansen L, et al. Induction of dormancy in hypoxic human papillomavirus-positive cancer cells. Proc Natl Acad Sci U S A. 2017;114(6):E990–E8.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  39. Curtis LT, England CG, Wu M, Lowengrub J, Frieboes HB. An interdisciplinary computational/experimental approach to evaluate drug-loaded gold nanoparticle tumor cytotoxicity. Nanomedicine (Lond). 2016;11(3):197–216.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  40. England CG, Gobin AM, Frieboes HB. Evaluation of uptake and distribution of gold nanoparticles in solid tumors. Eur Phys J Plus. 2015;130(11).

  41. England CG, Huang JS, James KT, Zhang G, Gobin AM, Frieboes HB. Detection of phosphatidylcholine-coated gold nanoparticles in Orthotopic pancreatic adenocarcinoma using hyperspectral imaging. PLoS One. 2015;10(6):e0129172.

    PubMed  PubMed Central  Article  Google Scholar 

  42. Curtis LT, Wu M, Lowengrub J, Decuzzi P, Frieboes HB. Computational modeling of tumor response to drug release from vasculature-bound nanoparticles. PLoS One. 2015;10(12):e0144888.

    PubMed  PubMed Central  Article  Google Scholar 

  43. Frieboes HB, Wu M, Lowengrub J, Decuzzi P, Cristini V. A computational model for predicting nanoparticle accumulation in tumor vasculature. PLoS One. 2013;8(2):e56876.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  44. van de Ven AL, Abdollahi B, Martinez CJ, Burey LA, Landis MD, Chang JC, et al. Modeling of nanotherapeutics delivery based on tumor perfusion. New J Phys. 2013;15:55004.

    PubMed  Article  Google Scholar 

  45. van de Ven AL, Wu M, Lowengrub J, McDougall SR, Chaplain MA, Cristini V, et al. Integrated intravital microscopy and mathematical modeling to optimize nanotherapeutics delivery to tumors. AIP Adv. 2012;2(1):11208.

    PubMed  Article  Google Scholar 

  46. England CG, Priest T, Zhang G, Sun X, Patel DN, McNally LR, et al. Enhanced penetration into 3D cell culture using two and three layered gold nanoparticles. Int J Nanomedicine. 2013;8:3603–17.

    PubMed  PubMed Central  Google Scholar 

  47. Frieboes HB, Edgerton ME, Fruehauf JP, Rose FR, Worrall LK, Gatenby RA, et al. Prediction of drug response in breast cancer using integrative experimental/computational modeling. Cancer Res. 2009;69(10):4484–92.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  48. Frieboes HB, Zheng X, Sun CH, Tromberg B, Gatenby R, Cristini V. An integrated computational/experimental model of tumor invasion. Cancer Res. 2006;66(3):1597–604.

    CAS  PubMed  Article  Google Scholar 

  49. Froehlich K, Haeger JD, Heger J, Pastuschek J, Photini SM, Yan Y, et al. Generation of multicellular breast Cancer tumor spheroids: comparison of different protocols. J Mammary Gland Biol Neoplasia. 2016;21(3–4):89–98.

    PubMed  Article  Google Scholar 

  50. Comerford KM, Wallace TJ, Karhausen J, Louis NA, Montalto MC, Colgan SP. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res. 2002;62(12):3387–94.

    CAS  PubMed  Google Scholar 

  51. Rice GC, Hoy C, Schimke RT. Transient hypoxia enhances the frequency of dihydrofolate reductase gene amplification in Chinese hamster ovary cells. Proc Natl Acad Sci U S A. 1986;83(16):5978–82.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  52. Rice GC, Ling V, Schimke RT. Frequencies of independent and simultaneous selection of Chinese hamster cells for methotrexate and doxorubicin (adriamycin) resistance. Proc Natl Acad Sci U S A. 1987;84(24):9261–4.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

Download references

Author information

Author notes

  1. Hermann B. Frieboes and Jill M. Steinbach-Rankins are joint senior authors.

Authors and Affiliations

  1. Department of Bioengineering, University of Louisville, 505 S. Hancock, CTR 623, Louisville, Kentucky, 40202, USA

    Lee B. Sims, Sindhu Parupalli, Hermann B. Frieboes & Jill M. Steinbach-Rankins

  2. Department of Biology, University of Louisville, Louisville, Kentucky, USA

    Keegan C. Curry

  3. School of Medicine, University of Louisville, Louisville, Kentucky, USA

    Gwynneth Horner

  4. James Graham Brown Cancer Center, University of Louisville, Louisville, Kentucky, USA

    Hermann B. Frieboes

  5. Department of Pharmacology and Toxicology, University of Louisville, Louisville, Kentucky, USA

    Hermann B. Frieboes & Jill M. Steinbach-Rankins

  6. Department of Microbiology and Immunology, University of Louisville, Louisville, Kentucky, USA

    Jill M. Steinbach-Rankins

  7. Center for Predictive Medicine, University of Louisville, Louisville, Kentucky, USA

    Jill M. Steinbach-Rankins

Authors
  1. Lee B. Sims
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Keegan C. Curry
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sindhu Parupalli
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gwynneth Horner
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hermann B. Frieboes
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jill M. Steinbach-Rankins
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jill M. Steinbach-Rankins.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Guest Editor: Joshua Reineke

Electronic supplementary material

ESM 1

(DOCX 148 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Sims, L.B., Curry, K.C., Parupalli, S. et al. Efficacy of Surface-Modified PLGA Nanoparticles as a Function of Cervical Cancer Type. Pharm Res 36, 66 (2019). https://doi.org/10.1007/s11095-019-2602-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s11095-019-2602-y

Key Words

  • 3D cell culture
  • cell penetrating peptide (CPP)
  • cervical cancer
  • nanoparticles
  • nanotherapy